Gamco Investors INC. ET AL Buys 63,700 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Gamco Investors INC. ET AL raised its stake in Bausch Health Companies Inc. (NYSE:BHC) by 4.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,440,945 shares of the company’s stock after acquiring an additional 63,700 shares during the period. Gamco Investors INC. ET AL’s holdings in Bausch Health Companies were worth $11,528,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Commonwealth Equity Services LLC boosted its stake in shares of Bausch Health Companies by 69.7% during the 2nd quarter. Commonwealth Equity Services LLC now owns 39,300 shares of the company’s stock worth $314,000 after purchasing an additional 16,148 shares during the period. Dimensional Fund Advisors LP increased its stake in Bausch Health Companies by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,733,882 shares of the company’s stock valued at $21,870,000 after purchasing an additional 309,522 shares in the last quarter. TD Asset Management Inc boosted its holdings in shares of Bausch Health Companies by 1.8% in the 2nd quarter. TD Asset Management Inc now owns 967,716 shares of the company’s stock valued at $7,752,000 after acquiring an additional 17,113 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of Bausch Health Companies by 57.4% in the 2nd quarter. Parallel Advisors LLC now owns 3,262 shares of the company’s stock valued at $26,000 after acquiring an additional 1,189 shares during the last quarter. Finally, Atria Wealth Solutions Inc. boosted its holdings in shares of Bausch Health Companies by 13.4% in the 2nd quarter. Atria Wealth Solutions Inc. now owns 30,377 shares of the company’s stock valued at $243,000 after acquiring an additional 3,600 shares during the last quarter. 74.56% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Bausch Health Companies

In other Bausch Health Companies news, EVP Seana Carson sold 6,685 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $8.28, for a total transaction of $55,351.80. Following the sale, the executive vice president now directly owns 385,213 shares of the company’s stock, valued at approximately $3,189,563.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 13.75% of the stock is owned by corporate insiders.

Bausch Health Companies Stock Performance

NYSE:BHC opened at $7.05 on Tuesday. The stock has a market cap of $2.54 billion, a PE ratio of -2.67 and a beta of 0.98. Bausch Health Companies Inc. has a fifty-two week low of $5.57 and a fifty-two week high of $10.23. The firm’s fifty day simple moving average is $7.56 and its 200-day simple moving average is $7.91. The company has a quick ratio of 0.89, a current ratio of 1.20 and a debt-to-equity ratio of 74.20.

Analysts Set New Price Targets

BHC has been the topic of a number of recent analyst reports. StockNews.com downgraded shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Jefferies Financial Group raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating and boosted their price target for the company from $9.00 to $16.00 in a research note on Wednesday, September 20th. Finally, Royal Bank of Canada lifted their price objective on shares of Bausch Health Companies from $8.00 to $9.00 and gave the company a “sector perform” rating in a report on Monday, July 24th.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified pharmaceutical company. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.